Spruce Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SPRB | PRQR | QNTM | DSGN | SLDB | PRTC.L | |
|---|---|---|---|---|---|---|
| Market cap | 133.96M | 198.98M | 14.21M | 665.24M | 699.11M | 302.55M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 9.4 | -3.0 | -0.3 | -6.6 | -3.8 | -5.1 |
| Price/book | 1.5 | 2.2 | 2.1 | 3.0 | 2.9 | 1.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −64.33% | −42.44% | −75.44% | +57.86% | +54.69% | −2.36% |
| Today | +8.88% | +2.92% | 0.00% | +2.80% | +3.82% | −0.64% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SPRB news ›Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
BioSpace Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stag
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
BioSpace Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company
GreenLight Biosciences 2026
Our platform creates high-quality, affordable RNA at scale Scaling biology in the service of humanity A diverse, compassionate, and qualified team Working at GreenLight Bio RNA can help tackle some of humanity’s greatest problems Our…
Spruce Biosciences, Inc. (NASDAQ:SPRB) Stock Rated “Moderate Buy” by Wall Street Analysts
Posted by Sarita Garza on Oct 13th, 2026 Get Our Latest Research Report on Spruce Biosciences Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported…
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
Spruce Biosciences, Inc. a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biospace.com1
- investingnews.com1
- stocktitan.net1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.